Ergotism is a poisoning syndrome caused by consuming grain contaminated with alkaloids produced by the fungus Claviceps purpurea, which infects rye and other cereals. For centuries it devastated European populations, earning names like “Saint Anthony’s fire” and “holy fire” for the searing pain and blackened limbs it produced in its victims.1Clinics in Dermatology. Ergotism: Historical Plagues to Modern Medical Insights The same alkaloids that caused those epidemics, though, turned out to be pharmacologically rich, and researchers eventually turned them into treatments for migraine, postpartum hemorrhage, and Parkinson’s disease. That transition from medieval plague to modern pharmacy is one of the stranger arcs in the history of medicine.
Saint Anthony’s Fire and the Medieval Epidemics
Rye was a staple grain across much of medieval Europe, especially in cooler, wetter climates where wheat struggled. Those same damp conditions were ideal for Claviceps purpurea, which infects the flowering heads of rye and replaces the developing grain kernels with dark, horn-shaped structures called sclerotia. Milled into flour alongside healthy grain, the sclerotia delivered a cocktail of potent alkaloids straight into the bread supply.
Epidemic after epidemic swept through European communities from roughly the ninth century onward. The disease was terrifying and mysterious: people developed an unbearable burning sensation in their extremities, followed by the blackening and eventual loss of fingers, toes, and whole limbs. The condition acquired many names, but “Saint Anthony’s fire” became the most enduring, because sufferers who made pilgrimages to the shrine of Saint Anthony in southern France sometimes recovered. The likely explanation is prosaic: the journey took them away from the contaminated grain supply, and their symptoms eased once they stopped eating it.
Outbreaks were not confined to any single century. Major epidemics recurred across France, Germany, and Scandinavia well into the 1700s, and smaller poisoning events were documented into the twentieth century. The link between contaminated rye and the disease was not firmly established until the early modern period, and before that, communities had little way to understand why entire villages fell ill simultaneously.
Two Forms of Poisoning
Ergotism presents in two broadly different ways depending on which alkaloids predominate and how much contaminated grain a person consumes. The gangrenous form is the one most people picture when they hear “Saint Anthony’s fire.” Ergot alkaloids cause intense and sustained constriction of blood vessels, particularly in the extremities. Blood flow drops, tissues starve, and gangrene sets in. The burning pain that gave the disease its medieval names comes from this vascular spasm, and in severe cases, limbs essentially die and fall off.2PubMed. Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors
The convulsive form is less visually dramatic but no less devastating. Victims experience violent muscle spasms, twitching, changes in mental state, hallucinations, sweating, and fever that can persist for weeks. A compelling hypothesis holds that convulsive ergotism is essentially an extended serotonin syndrome, caused by the alkaloids overstimulating serotonin receptors in the central nervous system. Ergot alkaloids are serotonin agonists, and the drug dihydroergotamine binds to serotonin receptors in the dorsal horn of the spinal cord, the very area where damage shows up in autopsies of convulsive ergotism cases.3PubMed. Convulsive ergotism: epidemics of the serotonin syndrome?
Whether a person developed the gangrenous or convulsive form historically depended partly on the specific alkaloid profile of the contaminated grain and partly on individual factors like nutritional status. Communities that were already malnourished, with poor vitamin A intake and restricted diets, may have been more susceptible to the vascular damage. Both forms could be fatal, and survivors of the gangrenous type often faced permanent disability.
The Salem Witch Trials Hypothesis
In the 1970s, historian Linnda Caporael proposed that the bizarre behavior of the accusers in the 1692 Salem witch panic might have been caused by convulsive ergotism. The idea gained a following and has been debated ever since. Proponents argued that weather conditions in Salem were suitable for ergot growth, that the ages of those who exhibited symptoms matched the demographic pattern of ergot poisoning, and that the symptoms reported, including convulsions, hallucinations, and altered mental states, overlapped with those of convulsive ergotism.
The hypothesis is more popular in casual history than among scholars. A critical analysis examined each of those propositions and rejected them, arguing that the events at Salem are more convincingly explained within a social-psychological framework.4PubMed. Ergotism and the Salem witch panic: a critical analysis and an alternative conceptualization The timeline does not fit well: symptoms of ergotism would have affected whole households rather than isolated individuals, the episodes in Salem came and went in ways inconsistent with chronic dietary exposure, and the social dynamics of accusation and confession have strong parallels in other witch panics where ergot was not a factor. The hypothesis remains a fascinating “what if” but is far from settled science.
The Fungus and Its Alkaloids
Claviceps purpurea is the most medically relevant species, but the genus is broader than most people realize. Different species target different crops in different climates: C. africana infects sorghum worldwide, while C. fusiformis infects pearl millet in Africa and Asia.5PubMed Central. Biology, genetics, and management of ergot (Claviceps spp.) in rye, sorghum, and pearl millet In sorghum and pearl millet, ergot became a particularly serious problem after growers adopted hybrid crop technology, which inadvertently increased the plants’ susceptibility to infection. Traits that help plants resist ergot include rapid pollination of receptive flowers and closed flowering, which limits the fungus’s window of opportunity to colonize the ovary.
The alkaloids these fungi produce share a common chemical backbone: lysergic acid, an indole compound derived from the amino acid tryptophan. Lysergic acid is the largest group of nitrogen-containing metabolites produced by any fungus.6PubMed Central. Methods of Lysergic Acid Synthesis-The Key Ergot Alkaloid The fungus assembles this backbone into two main classes of finished alkaloid. In the ergopeptines, such as ergotamine, lysergic acid is linked to a three-part peptide chain. In the simpler lysergyl-alkanolamides, it is linked to a single amino alcohol derived from the amino acid alanine.7PubMed Central. Combinatorial assembly of simple and complex D-lysergic acid alkaloid peptide classes in the ergot fungus Claviceps purpurea This structural variety is what gives ergot alkaloids such a wide range of biological effects, from blood vessel constriction to serotonin receptor activation to dopamine mimicry.
From an evolutionary standpoint, the alkaloids serve the fungus well. They act as feeding deterrents, discouraging herbivores from eating infected plant tissue. Some researchers have framed this as a protective mutualism: the fungus infects the plant, but the toxins it produces may also shield the host from being consumed.8PubMed. Evolutionary history of ergot with a new infrageneric classification (Hypocreales: Clavicipitaceae: Claviceps) Related fungi in the family Clavicipitaceae, which live as symbionts inside grasses, use similar toxic alkaloid chemistry to protect their host plants from herbivores.9PubMed Central. Horizontal acquisition of toxic alkaloid synthesis in a clade of plant associated fungi
From Poison to Migraine Drug
The pharmacological usefulness of ergot was recognized long before anyone understood the chemistry. Folk medicine traditions used crude ergot preparations to hasten labor and control bleeding, though the doses were wildly unpredictable and poisoning was a constant risk. The real breakthrough came in 1918, when Arthur Stoll at Sandoz Pharmaceuticals in Basel isolated ergotamine from the alkaloid mixture in ergot sclerotia.10PubMed. The history of ergot of rye (Claviceps purpurea) II: 1900-1940 By 1925, ergotamine was being used clinically to treat migraine attacks.11PubMed. Ergot of rye-the first specific for migraine
Ergotamine and its derivative dihydroergotamine work against migraine by acting on the same serotonin receptor subtypes, 5-HT1B and 5-HT1D, that are now the main targets for modern migraine drugs. They constrict the dilated blood vessels around the brain that contribute to migraine pain, and they inhibit pain signaling in the trigeminal nerve system. The clinical evidence for dihydroergotamine is stronger than for ergotamine itself.12PubMed. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy Both compounds are highly potent at the relevant receptors, meaning very low blood concentrations can produce therapeutic effects, but they also hit many other receptor types, which is the root of their side-effect problems.
The triptans, introduced in the 1990s, were designed to hit the same 5-HT1B and 5-HT1D receptors with much greater selectivity, avoiding the broad receptor promiscuity that makes ergot drugs problematic.13PubMed. The 5-HT(1B) and 5-HT(1D) agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans Triptans largely replaced ergotamine for most patients, though dihydroergotamine still has a niche. It remains useful for severe or prolonged migraines that do not respond to triptans, partly because its sustained vasoconstrictor action can prevent the headache from coming back.
Ergot Derivatives in Obstetrics
Ergot alkaloids contract the smooth muscle of the uterus with striking force, and this property has been used to control postpartum hemorrhage, which remains one of the leading causes of maternal death worldwide. The two main ergot-derived drugs in obstetric use are ergometrine (more common outside the United States) and methylergonovine (the standard in the U.S.). Both cause uterine contractions within one to three minutes of administration and have long half-lives, reaching peak blood levels in about forty minutes.14PubMed Central. Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone pharmacologic therapy – Section: Ergot alkaloids (ergometrine, ergonovine, methylergonovine)
Ergometrine is recommended in guidelines for treating postpartum hemorrhage and is used around the world.15PubMed Central. Ergometrine for postpartum hemorrhage and associated myocardial ischemia: Two case reports and a review of the literature Recent research has also explored combining ergometrine maleate with calcium gluconate for preventing hemorrhage caused by uterine atony, the most common trigger. In one study, the combination produced significantly lower postpartum blood loss, shorter labor stages, and higher hemoglobin levels at twenty-four hours compared to standard approaches.16PubMed. Clinical Efficacy of Calcium Gluconate Combined With Ergometrine Maleate in the Prevention of Uterine Atony-Induced Postpartum Hemorrhage and Their Effects on Coagulation Function
The trade-off is that these drugs constrict blood vessels everywhere, not just in the uterus. Ergometrine has been associated with myocardial ischemia in case reports, which is why it is used cautiously in women with cardiovascular risk factors. They are powerful tools, but not ones clinicians reach for carelessly.
Ergot Alkaloids and Parkinson’s Disease
One of the more surprising chapters in ergot pharmacology involves Parkinson’s disease. Because ergot alkaloids interact with dopamine receptors, and Parkinson’s is fundamentally a disease of dopamine deficiency in the brain, several ergot-derived drugs were developed as dopamine agonists. Bromocriptine, an ergopeptine derivative, was the first widely used. It works primarily by stimulating D2 dopamine receptors in the striatum. In patients with mild to moderate disease, low doses were effective; higher doses were needed for advanced disease, and combining bromocriptine with levodopa typically worked better than either alone.17PubMed. Bromocriptine in Parkinson disease
Other ergot-derived dopamine agonists followed, including pergolide and lisuride. Receptor-binding studies showed that all three had strong affinity for D2 receptors, and their optimal clinical doses tracked closely with how tightly they bound to that receptor.18PubMed. Dopamine agonists used in the treatment of Parkinson’s disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum These drugs offered real benefits, but they also carried a serious risk that eventually reshaped prescribing practices worldwide.
The Fibrosis Problem That Changed Prescribing
Through the 2000s, mounting evidence showed that ergot-derived dopamine agonists, particularly cabergoline and pergolide, could cause fibrotic changes in heart valves. The problem was not subtle: patients developed thickened, stiffened valves that in some cases required surgical replacement. Pharmacovigilance data confirmed that the reporting odds ratios for fibrotic reactions were elevated for all the ergot-derived drugs, including bromocriptine, cabergoline, and pergolide, while no such increases were seen for the newer non-ergot dopamine agonists like pramipexole, ropinirole, and rotigotine.19PubMed. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists
Fibrotic reactions were not limited to heart valves. Pulmonary fibrosis and retroperitoneal fibrosis, conditions involving scarring of lung tissue and the tissue behind the abdominal organs, were also reported at elevated rates with ergot-derived drugs. The mechanism appears to involve 5-HT2B serotonin receptor activation, which stimulates fibroblast proliferation. Ergot-derived agonists hit this receptor; non-ergot agonists largely do not. This safety gap led most clinical guidelines to shift away from ergot-derived dopamine agonists as first-line therapy for Parkinson’s disease, reserving them for situations where the newer drugs are insufficient or unavailable.
Drug Interactions and Modern Ergotism
Ergotism has not vanished. It still occurs, though not from contaminated bread. The modern version is almost always iatrogenic, caused by drug interactions in patients taking ergotamine or dihydroergotamine for migraine. Ergot alkaloids are metabolized in the liver by the CYP3A4 enzyme system. When a patient takes another drug that strongly inhibits CYP3A4, ergotamine blood levels can spike dramatically, causing the same vasospasm and peripheral ischemia that medieval sufferers experienced.
In one case series, three-quarters of the ergotism cases were precipitated by drug interactions with CYP3A4 inhibitors, and over eighty percent of patients showed signs of peripheral vascular insufficiency.2PubMed. Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors HIV protease inhibitors are among the most potent CYP3A4 inhibitors in clinical use, and the combination with ergot drugs has caused life-threatening ischemia. One case involved a woman taking dihydroergotamine for low blood pressure who was prescribed HIV post-exposure prophylaxis including lopinavir and ritonavir. Within a day she developed acute bilateral leg ischemia, with sudden calf pain and ischemic toes. Angiography confirmed diffuse arterial vasospasm.20PubMed. Ergotism with acute limb ischemia, provoked by HIV protease inhibitors interaction with ergotamine, rescued by multisite transluminal balloon angioplasty Another case report documented a fatal outcome from the combination of ergotamine with antiretroviral therapy including darunavir.21PubMed Central. Drug-Drug Interaction of Ergotamine with a Combination of Darunavir, Abacavir, and Lamivudine Causing a Fatal Vasospastic Ischemia
Other CYP3A4 inhibitors that can trigger the same problem include certain antifungal drugs and macrolide antibiotics. The risk is underestimated in everyday practice partly because ergotamine use has declined, making the interaction unfamiliar to many prescribers. When modern ergotism does present, imaging with duplex ultrasound or angiography can confirm the diffuse vasospasm. Treatment involves immediately stopping the ergot drug, administering vasodilators such as intravenous nitroprusside or intra-arterial prostaglandin, and addressing any contributing factors.22PubMed Central. Ergotism with ischemia in all four extremities: a case report In one published case involving all four extremities, stopping ergotamine, giving nitroprusside, and quitting smoking led to full resolution of the arterial spasm on follow-up imaging.23PubMed Central. Ergotism: Case Report and Review of the Literature
Fescue Toxicosis in Livestock
Humans are no longer the primary victims of ergot alkaloid poisoning. That distinction now belongs to livestock, particularly cattle grazing on tall fescue grass infected with a related endophytic fungus. Fescue toxicosis causes economic losses estimated at more than two billion dollars annually in the United States alone. The clinical picture in cattle resembles historical human ergotism in miniature: reduced feed intake, poor weight gain, decreased milk production, reproductive problems, elevated body temperature, and in severe cases, vasoconstriction leading to gangrene of extremities, a condition known as “fescue foot.”24PubMed Central. Fescue toxicosis: a detrimental condition that requires a multiapproach solution
Managing fescue toxicosis is a major ongoing challenge for the livestock industry. Strategies include replacing toxic fescue pastures with endophyte-free or “novel endophyte” varieties that harbor fungal strains producing fewer harmful alkaloids, diluting toxic pasture by mixing in other grass or legume species, and adjusting grazing timing to avoid periods of peak alkaloid production. The problem is a vivid reminder that the ergot alkaloid story is not merely historical. The same fundamental chemistry that plagued medieval villagers is still poisoning animals on modern farms.
Food Safety Regulations Today
For the human food supply, ergot contamination is managed through a combination of agricultural practice and regulatory limits. The approaches differ around the world. The European Union has adopted chemical limits for the total concentration of ergot alkaloids in cereal products, consolidated under Commission Regulation 2023/915, which sets maximum levels for ergot sclerotia and for the sum of twelve specific ergot alkaloids, including their chemical mirror-image forms, in specified cereal products.25PubMed Central. Innovative Detection and Mitigation of Ergot Alkaloids in Cereals: Advancing Food Safety – Section: Compliance with EU Maximum Levels and Best Practice Pathway Other regions, including parts of North America, rely more on visual grading systems that measure the amount of sclerotia present in a grain lot rather than testing for the alkaloids directly.26PubMed Central. Monitoring and Managing of Ergot Alkaloids in Cereal Grains: A Comprehensive Analysis of Analytical Challenges, Sampling Uncertainty, and Processing for Food Safety
The chemical-limit approach is generally considered more protective, because sclerotia can vary widely in their alkaloid content depending on the fungal strain, the host crop, and growing conditions. A grain lot that looks acceptable by sclerotia count might still carry high alkaloid levels, or vice versa. Sampling itself is a challenge: ergot sclerotia are not evenly distributed through a grain shipment, so the alkaloid concentration measured in one sample may not represent the whole lot accurately. Food processing steps like milling and baking reduce alkaloid levels to some extent, but do not eliminate them entirely. For consumers in countries with modern grain inspection, the risk of ergotism from bread is effectively zero, but the monitoring infrastructure that makes that possible is more elaborate than most people realize.
LSD and the Psychedelic Connection
No article on ergot alkaloids would be complete without acknowledging the most famous compound ever derived from them. In 1938, Albert Hofmann, working at the same Sandoz laboratory where Stoll had isolated ergotamine two decades earlier, synthesized lysergic acid diethylamide, later known as LSD-25. He was not looking for a psychedelic; he was systematically modifying ergot alkaloid structures to find useful pharmaceuticals. Five years later, in 1943, he accidentally absorbed a small amount and experienced the first LSD trip in history.
LSD’s extraordinary potency, active at microgram doses, flows directly from the lysergic acid backbone it shares with natural ergot alkaloids. It acts primarily on serotonin 5-HT2A receptors, producing the perceptual distortions and altered consciousness that defined psychedelic culture from the 1960s onward. The connection to ergotism is more than genealogical: some historians have speculated that the hallucinations reported during convulsive ergotism epidemics may have reflected similar serotonergic overstimulation, though at much less predictable doses and in combination with a suite of other toxic alkaloids that made the experience anything but recreational. The distance from a medieval rye field to a modern clinical trial of psychedelic therapy is shorter than it looks, chemically speaking.